Biofourmis vs Hippocratic AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Biofourmis employs 100-500 people, while Hippocratic AI has 50-200 employees.

Biofourmis has raised more in total funding at $445M, compared to Hippocratic AI's $120M — a gap of $325M.

Biofourmis holds the higher Awaira Score at 73/100, compared to Hippocratic AI's 65/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 8-point gap that reflects meaningful differences in scale or traction.

Biofourmis was founded by Kuldeep Singh in 2015. Hippocratic AI was founded by Munjal Shah in 2023. Visit each company's profile on Awaira for a full founder biography.

Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting. Hippocratic AI: Hippocratic AI develops a safety-focused AI platform designed to address the global shortage of healthcare professionals by deploying AI agents that perform patient-facing healthcare communication tasks including care navigation, medication adherence outreach, chronic disease monitoring, and post-discharge follow-up. The platform is built around a healthcare-specific large language model with extensive safety evaluation against clinical benchmarks.\n\nThe company raised approximately 120 million USD in early rounds and has established partnerships with health systems and payers focused on reducing care gaps and improving patient engagement at scale. Hippocratic positions its AI as augmenting the healthcare workforce rather than replacing clinicians, targeting the vast volume of lower-acuity patient interactions that do not require physician judgment.\n\nThe healthcare staffing shortage is a structural problem projected to worsen over the next decade, creating durable demand for AI solutions that extend the capacity of existing clinical teams. Hippocratic AI competes with ambient clinical AI companies and general-purpose AI assistant platforms, but its narrow vertical focus on patient-facing healthcare communication and its safety-first design philosophy position it to navigate the regulatory and liability landscape that general AI platforms are less equipped to manage.

Biofourmis was founded first in 2015, giving it 8 years of additional market experience. Hippocratic AI was founded later in 2023. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Biofourmis has approximately 100-500 employees, while Hippocratic AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Biofourmis and Hippocratic AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.